Dossier assessment
Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with symptomatic chronic heart failure with reduced ejection fraction
Hint of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.
Project details
- Project no.
- A21-93
- Commission
- Commission awarded on 13.07.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Empagliflozin - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed